目的 探討納入國家醫(yī)保談判（以下簡稱“國談”）藥品目錄的新型抗腫瘤藥物在山西省的可獲得性及使用情況，為后續(xù)省級政策優(yōu)化提供數(shù)據(jù)支撐。方法 收集2022—2024年山西省“國談”新型抗腫瘤藥物使用數(shù)據(jù)，運用描述性統(tǒng)計分析方法，對356家公立二、三級醫(yī)院“國談”新型抗腫瘤藥物的可獲得率、用藥金額、用藥頻度（DDDs）、日均費用（DDC）及排序比（B/A）指標進行分析。結(jié)果 “國談”新型抗腫瘤藥物整體可獲得率逐年上升，三級醫(yī)院的獲得率明顯高于二級醫(yī)院，但可獲得率中位數(shù)評價均為“非常低”。與2022年相比，2023年“國談”新型抗腫瘤藥物的藥物利用指標DDDs和用藥金額分別增長32.39%和31.68%，2024年DDDs和用藥金額分別增長40.54%和24.65%，DDC整體呈現(xiàn)不同程度的下降趨勢，3種國產(chǎn)新藥替雷利珠單抗、信迪利單抗、卡瑞利珠單抗其銷售金額和DDDs值均位于排名前5內(nèi)，且B/A＞1。結(jié)論 “國談”新型抗腫瘤藥物在山西省的可獲得率不高，利用情況2年來呈合理上升趨勢，省級衛(wèi)生主管部門應(yīng)優(yōu)化“國談”藥品政策的落地實施，提高可獲得率，同時加強臨床合理用藥監(jiān)管。

Objective To investigate the availability and utilization of new anticancer drugs included in the national medical insurance negotiation drug list in Shanxi province, and to provide data support for subsequent provincial policy optimization.Merhods The data of the use of new anticancer drugs drugs in the province from 2022 to 2024 were collected. Descriptive statistical analysis was used to analyze the indicators such as availability rate, expense, DDDs, DDC, and B/A of new anticancer drugs in 356 secondary and tertiary public general hospitals in Shanxi province.Results The overall availability rate of national negotiation new anticancer drugs were increased. Availability rate of tertiary general hospitals was significantly higher than that of secondary general hospitals, but the median evaluation of the availability rate was “very low”. Compared with 2022, the drug utilization index DDDs and drug expenditure of national negotiation new anticancer drugs in 2023 were increased by 32.39% and 31.68%, increased by 40.54% and 24.65% in 2024, and DDC showed a downward trend to varying degrees. The expense and DDDs of three domestic new drugs for tirellizumab, sintilizumab, and camrelizumab were all in the top five, and B/A > 1.Conclusion The availability rate of new national negotiation anticancer drugs is not high in Shanxi province, and consumption shows a reasonable upward trend in the past two years. The provincial health authorities should optimize the implementation of the drug policy, improve the availability, and strengthen the supervision of rational clinical drug use.

R979.1

山西省大健康產(chǎn)業(yè)高質(zhì)量發(fā)展科研專項課題（DJKZXKT2023264）；國家衛(wèi)生健康委醫(yī)院管理研究所醫(yī)院藥學高質(zhì)量發(fā)展研究項目（NIHAYS2428）